Liu TP - Search Results

1

Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining.

Liu TP, Hsieh YY, Chou CJ, Yang PM. Liu TP, et al. R Soc Open Sci. 2018 Nov 28;5(11):181321. doi: 10.1098/rsos.181321. eCollection 2018 Nov. R Soc Open Sci. 2018. PMID: 30564416 Free PMC article.

2

S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.

Liu TP, Lo HL, Wei LS, Hsiao HH, Yang PM. Liu TP, et al. Anticancer Drugs. 2015 Feb;26(2):139-47. doi: 10.1097/CAD.0000000000000166. Anticancer Drugs. 2015. PMID: 25203626 Free PMC article.

3

In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.

Liu TP, Hong YH, Tung KY, Yang PM. Liu TP, et al. Oncoscience. 2016 Jan 29;3(1):9-20. doi: 10.18632/oncoscience.285. eCollection 2016. Oncoscience. 2016. PMID: 26973856 Free PMC article.

4

In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells.

Liu TP, Hong YH, Yang PM. Liu TP, et al. Oncotarget. 2017 Sep 16;8(49):86168-86180. doi: 10.18632/oncotarget.21030. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156785 Free PMC article.

5

In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinoma.

Hsieh YY, Liu TP, Yang PM. Hsieh YY, et al. Among authors: liu tp. Pathol Res Pract. 2019 Jun;215(6):152373. doi: 10.1016/j.prp.2019.03.002. Epub 2019 Mar 4. Pathol Res Pract. 2019. PMID: 30871916

6

Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.

Hsieh YY, Liu TP, Chou CJ, Chen HY, Lee KH, Yang PM. Hsieh YY, et al. Among authors: liu tp. Genes (Basel). 2019 Sep 28;10(10):766. doi: 10.3390/genes10100766. Genes (Basel). 2019. PMID: 31569425 Free PMC article.

7

p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.

Yang PM, Hong YH, Hsu KC, Liu TP. Yang PM, et al. Among authors: liu tp. Am J Cancer Res. 2019 Oct 1;9(10):2120-2139. eCollection 2019. Am J Cancer Res. 2019. PMID: 31720078 Free PMC article.

8

Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.

Yang PM, Lin LS, Liu TP. Yang PM, et al. Among authors: liu tp. Biomolecules. 2020 Jan 9;10(1):117. doi: 10.3390/biom10010117. Biomolecules. 2020. PMID: 31936661 Free PMC article.

9

CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study.

Lin JC, Liu TP, Yang PM. Lin JC, et al. Among authors: liu tp. J Clin Med. 2020 Dec 12;9(12):4019. doi: 10.3390/jcm9124019. J Clin Med. 2020. PMID: 33322698 Free PMC article.

10

PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells.

Lin JC, Yang PM, Liu TP. Lin JC, et al. Among authors: liu tp. Int J Mol Sci. 2021 May 29;22(11):5848. doi: 10.3390/ijms22115848. Int J Mol Sci. 2021. PMID: 34072570 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

205 results

Search Page

Filters